| Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin … A Dueñas-González, JJ Zarbá, F Patel, JC Alcedo, S Beslija, L Casanova, ... | 529 | 2009 |
| Third consensus on medical treatment of metastatic breast cancer S Beslija, J Bonneterre, HJ Burstein, V Cocquyt, M Gnant, V Heinemann, ... Annals of oncology 20 (11), 1771-1785, 2009 | 241 | 2009 |
| Second consensus on medical treatment of metastatic breast cancer S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, ... Annals of oncology 18 (2), 215-225, 2007 | 149 | 2007 |
| Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial J Ocvirk, T Brodowicz, F Wrba, TE Ciuleanu, G Kurteva, S Beslija, I Koza, ... World journal of gastroenterology: WJG 16 (25), 3133, 2010 | 138 | 2010 |
| Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised … I Lang, T Brodowicz, L Ryvo, Z Kahan, R Greil, S Beslija, SM Stemmer, ... The lancet oncology 14 (2), 125-133, 2013 | 119 | 2013 |
| Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European … C Zielinski, S Beslija, Z Mrsic-Krmpotic, M Welnicka-Jaskiewicz, ... Journal of clinical oncology 23 (7), 1401-1408, 2005 | 79 | 2005 |
| Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a … C Zielinski, I Láng, M Inbar, Z Kahán, R Greil, S Beslija, SM Stemmer, ... The Lancet Oncology 17 (9), 1230-1239, 2016 | 68 | 2016 |
| Cancer control in Central and Eastern Europe: Current situation and recommendations for improvement E Vrdoljak, G Bodoky, J Jassem, RA Popescu, J Mardiak, R Pirker, ... The Oncologist 21 (10), 1183-1190, 2016 | 56 | 2016 |
| Targeting HER2 expression in cancer: New drugs and new indications S Vranić, S Bešlija, Z Gatalica Bosnian journal of basic medical sciences 21 (1), 1, 2021 | 54 | 2021 |
| Colorectal cancer surgical treatment, our experience M Salibasic, S Pusina, E Bicakcic, A Pasic, I Gavric, E Kulovic, A Rovcanin, ... Medical Archives 73 (6), 412, 2019 | 52 | 2019 |
| A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low-and … Y Belkacemi, N Grellier, S Ghith, K Debbi, G Coraggio, A Bounedjar, ... European Journal of Cancer 135, 130-146, 2020 | 45 | 2020 |
| A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma MF Kose, J Sufliarsky, S Beslija, P Saip, G Tulunay, K Krejcy, T Minarik, ... Gynecologic oncology 96 (2), 374-380, 2005 | 37 | 2005 |
| Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with … S Beslija, N Obralic, H Basic, A Tatarevic, M Naila, M Banjin, A Cardzic, ... Journal of Clinical Oncology 24 (18_suppl), 571-571, 2006 | 36 | 2006 |
| A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients … A Dueñas-González, JJ Zarba, JC Alcedo, P Pattarunataporn, S Beslija, ... Journal of Clinical Oncology 27 (18_suppl), CRA5507-CRA5507, 2009 | 35 | 2009 |
| Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses T Brodowicz, I Láng, Z Kahán, R Greil, S Beslija, SM Stemmer, B Kaufman, ... British journal of cancer 111 (11), 2051-2057, 2014 | 32 | 2014 |
| Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer C Zielinski, I Lang, S Beslija, Z Kahan, MJ Inbar, SM Stemmer, R Anghel, ... British Journal of Cancer 114 (2), 163-170, 2016 | 31 | 2016 |
| The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer N Bilalovic, S Vranic, S Hasanagic, H Basic, A Tatarevic, S Beslija, I Selak Bosnian journal of basic medical sciences 4 (4), 5, 2004 | 27 | 2004 |
| Expenditures on oncology drugs and cancer mortality‐to‐incidence ratio in Central and Eastern Europe E Vrdoljak, G Bodoky, J Jassem, R Popescu, R Pirker, T Čufer, S Bešlija, ... The Oncologist 24 (1), e30-e37, 2019 | 23 | 2019 |
| Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or … I Lang, MJ Inbar, Z Kahán, R Greil, S Beslija, SM Stemmer, B Kaufman, ... European Journal of Cancer 48 (17), 3140-3149, 2012 | 23 | 2012 |
| Investigation of IVS14+ 1G> A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine T Cerić, N Obralić, L Kapur-Pojskić, D Macić, S Bešlija, A Pašić, Š Cerić Bosnian journal of basic medical sciences 10 (2), 133, 2010 | 22 | 2010 |
